NVCR raises 2026 revenue guidance to $710M-$725M after surpassing Q2 estimates, topping consensus of $708.73M.
NovoCure (NVCR) raised its full-year revenue guidance to $710M-$725M from $690M-$710M after reporting stronger-than-expected Q2 results. The oncology company’s updated outlook exceeds consensus estimates of $708.73M.
Prior guidance had set revenue between $690M and $710M. The revised range reflects improved performance in the quarter, though specific Q2 figures were not detailed in the update.
Shares surged approximately 25% in early Thursday trading following the announcement.